conflict with the subject matter or materials discussed in the manuscript apart from those
disclosed.
References
(1) Association, A. D.: Diagnosis and Classification of Diabetes Mellitus. 2012, 101, 274.
(2) Sarwar, N.; Gao, P.; Seshasai, S. R.; Gobin, R.; Kaptoge, S.; Di, A. E.; Ingelsson, E.; Lawlor, D.
A.; Selvin, E.; Stampfer, M.: Diabetes mellitus, fasting blood glucose concentration, and risk of
vascular disease: a collaborative meta-analysis of 102 prospective studies. The Lancet, 2010, 375,
2215.
(3) Whiting, D. R.; Leonor, G.; Clara, W.; Jonathan, S.: IDF Diabetes Atlas: Global estimates of the
prevalence of diabetes for 2011 and 2030. 2011, 094, 0-321.
(4) La Motta, C.; Sartini, S.; Salemo, S.; Simorini, F.; Taliani, S.; Marini, A. M.; Da Settimo, F.;
Marinelli, L.; Limongelli, V.; Novellino, E.: Acetic acid aldose reductase inhibitors bearing a
five-membered heterocyclic core with potent topical activity in a visual impairment rat model. Journal
of Medicinal Chemistry, 2008, 51, 3182-3193.
(5) Maccari, R.; Ottana, R.; Ciurleo, R.; Vigorita, M. G.; Rakowitz, D.; Steindl, T.; Langer, T.:
Evaluation of in vitro aldose redutase inhibitory activity of 5-arylidene-2,4-thiazolidinediones.
Bioorganic & Medicinal Chemistry Letters, 2007, 17, 3886-3893.
(6) Stefek, M.; Soltesova Prnova, M.; Majekova, M.; Rechlin, C.; Heine, A.; Klebe, G.: Identification
of Novel Aldose Reductase Inhibitors Based on Carboxymethylated Mercaptotriazinoindole Scaffold.
Journal of Medicinal Chemistry, 2015, 58, 2649-2657.
(7) Brownlee, M.: Biochemistry and molecular biology of diabetic complications. Nature, 2001, 414.
(8) Hao, X.; Han, Z.; Li, Y.; Li, C.; Wang, X.; Zhang, X.; Yang, Q.; Ma, B.; Zhu, C.: Synthesis and
structure–activity relationship studies of phenolic hydroxyl derivatives based on quinoxalinone as
aldose reductase inhibitors with antioxidant activity. Bioorganic & Medicinal Chemistry Letters, 2017,
27, 887-892.
(9) Chen, X.; Zhu, C.; Guo, F.; Qiu, X.; Yang, Y.; Zhang, S.; He, M.; Parveen, S.; Jing, C.; Li, Y.;
Ma, B.: Acetic Acid Derivatives of 3,4-Dihydro-2H-1,2,4-benzothiadiazine 1,1-Dioxide as a Novel
Class of Potent Aldose Reductase Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 8330-8344.
(10) Shukla, K.; Sonowal, H.; Saxena, A.; Ramana, K. V.; Srivastava, S. K.: Aldose reductase
inhibitor, fidarestat regulates mitochondrial biogenesis via Nrf2/HO1/AMPK pathway in colon cancer
cells. Cancer Letters, 2017, 1, 1-7.
(11) Tammali, R.; Saxena, A.; Srivastava, S. K.; Ramana, K. V.: Aldose Reductase Inhibition Prevents
Hypoxia-induced Increase in Hypoxia-inducible Factor-1α (HIF-1α) and Vascular Endothelial Growth
Factor (VEGF) by Regulating 26 S Proteasome-mediated Protein Degradation in Human Colon Cancer
Cells *. Journal of Biological Chemistry, 2011, 27(286), 24089-24100.
(12) Papastavrou, N.; Chatzopoulou, M.; Ballekova, J.; Cappiello, M.; Moschini, R.; Balestri, F.;
Patsilinakos, A.; Ragno, R.; Stefek, M.; Nicolaou, I.: Enhancing activity and selectivity in a series of
pyrrol-1-yl-1-hydroxypyrazole-based aldose reductase inhibitors: The case of trifluoroacetylation.
European Journal of Medicinal Chemistry, 2017, 130, 328-335.
(13) Kotsampasakou, E.; Demopoulos, V. J.: Synthesis of derivatives of the
keto-pyrrolyl-difluorophenol scaffold: Some structural aspects for aldose reductase inhibitory activity
and selectivity. Bioorganic & Medicinal Chemistry, 2013, 21, 869-873.
11